Skip to main content

Advertisement

SpringerLink
Log in

The Role of Radiation Therapy for Symptomatic Desmoid Tumors

  • Sarcoma (SH Okuno, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Desmoid tumors have a variable clinical course that ranges from indolence or spontaneous regression to an aggressive pattern marked by local invasion. Up to half may remain stable or regress; watchful waiting is the preferred approach in the initial management of desmoid tumors. Symptomatic or progressive tumors or those that may affect adjacent critical structures require surgery, radiotherapy, or systemic therapy. Although radiotherapy effectively controls desmoid tumors in most cases, concerns regarding late toxicity exist. Definitive radiotherapy for macroscopic disease is indicated when a non-morbid complete surgical resection cannot be accomplished and provides similar control rates to surgery plus radiotherapy but avoids toxicity from combined-modality treatment (surgery and radiotherapy). Adjuvant radiotherapy can be considered for microscopically involved margins, particularly for recurrent cases or when a future recurrence may be challenging to treat. Large size, extremity site, and younger age are poor prognostic factors after radiotherapy. In the extremity, radiotherapy may have superior outcomes to surgery. Younger patients, especially children, are challenging to manage as they are at particular risk for late toxicity due to the number of potential years at risk. For patients under 20 years old, for whom a non-morbid complete resection is not possible, we recommend systemic therapy as the first line of treatment. Although the long-term efficacy of systemic therapy is unproven, this strategy allows additional time for growth and development prior to radiotherapy. In younger patients and those with axial desmoid tumors adjacent to critical organs, consideration should be given to using proton therapy as the dosimetric advantages may mitigate some of the toxicity associated with conventional radiotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Micke O, Seegenschmiedt MH. Radiation therapy for aggressive fibromatosis (desmoid tumors): results of a national Patterns of Care Study. Int J Radiat Oncol Biol Phys. 2005;61(3):882–91.

    Article  PubMed  Google Scholar 

  2. Reitamo JJ, Häyry P, Nykyri E, Saxén E. The desmoid tumor. I. Incidence, sex-, age- and anatomical distribution in the Finnish population. Am J Clin Pathol. 1982;77(6):665–73.

    Article  CAS  PubMed  Google Scholar 

  3. van Broekhoven DL, Grünhagen DJ, den Bakker MA, van Dalen T, Verhoef C. Time trends in the incidence and treatment of extra-abdominal and abdominal aggressive fibromatosis: a population-based study. Ann Surg Oncol. 2015;22(9):2817–23.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Kasper B, Ströbel P, Hohenberger P. Desmoid tumors: clinical features and treatment options for advanced disease. Oncologist. 2011;16(5):682–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Koskenvuo L, Ristimäki A, Lepistö A. Comparison of sporadic and FAP-associated desmoid-type fibromatoses. J Surg Oncol. 2017;116(6):716–21.

    Article  CAS  PubMed  Google Scholar 

  6. Fallen T, Wilson M, Morlan B, Lindor NM. Desmoid tumors -- a characterization of patients seen at Mayo Clinic 1976-1999. Familial Cancer. 2006;5(2):191–4.

    Article  PubMed  Google Scholar 

  7. Nieuwenhuis MH, Casparie M, Mathus-Vliegen LM, Dekkers OM, Hogendoorn PC, Vasen HF. A nation-wide study comparing sporadic and familial adenomatous polyposis-related desmoid-type fibromatoses. Int J Cancer. 2011;129(1):256–61.

    Article  CAS  PubMed  Google Scholar 

  8. Lewis JJ, Boland PJ, Leung DH, Woodruff JM, Brennan MF. The enigma of desmoid tumors. Ann Surg. 1999;229(6):866–72 discussion 72-3.

  9. Gansar GF, Markowitz IP, Cerise EJ. Thirty years of experience with desmoid tumors at Charity Hospital. Am Surg. 1987;53(6):318–9.

    CAS  PubMed  Google Scholar 

  10. Fiore M, Coppola S, Cannell AJ, Colombo C, Bertagnolli MM, George S, et al. Desmoid-type fibromatosis and pregnancy: a multi-institutional analysis of recurrence and obstetric risk. Ann Surg. 2014;259(5):973–8.

    Article  PubMed  Google Scholar 

  11. Hayry P, Reitamo JJ, Totterman S, Hopfner-Hallikainen D, Sivula A. The desmoid tumor. II. Analysis of factors possibly contributing to the etiology and growth behavior. Am J Clin Pathol. 1982;77(6):674–80.

    Article  CAS  PubMed  Google Scholar 

  12. Eastley N, Aujla R, Silk R, Richards CJ, McCulloch TA, Esler CP, et al. Extra-abdominal desmoid fibromatosis--a sarcoma unit review of practice, long term recurrence rates and survival. Eur J Clin Oncol. 2014;40(9):1125–30.

  13. Escobar C, Munker R, Thomas JO, Li BD, Burton GV. Update on desmoid tumors. Ann Oncol. 2012;23(3):562–9.

    Article  CAS  PubMed  Google Scholar 

  14. Walczak BE, Rose PS. Desmoid: the role of local therapy in an era of systemic options. Curr Treat Options in Oncol. 2013;14(3):465–73.

    Article  Google Scholar 

  15. Colombo C, Miceli R, Le Péchoux C, Palassini E, Honoré C, Stacchiotti S, et al. Sporadic extra abdominal wall desmoid-type fibromatosis: surgical resection can be safely limited to a minority of patients. Eur J Cancer (Oxford England : 1990). 2015;51(2):186–92.

    Article  CAS  Google Scholar 

  16. Bonvalot S, Ternès N, Fiore M, Bitsakou G, Colombo C, Honoré C, et al. Spontaneous regression of primary abdominal wall desmoid tumors: more common than previously thought. Ann Surg Oncol. 2013;20(13):4096–102.

    Article  PubMed  Google Scholar 

  17. Roussin S, Mazouni C, Rimareix F, Honoré C, Terrier P, Mir O, et al. Toward a new strategy in desmoid of the breast? Eur J Surg Oncol. 2015;41(4):571–6.

    Article  CAS  PubMed  Google Scholar 

  18. •• Bates JE, Morris CG, Iovino NM, Rutenberg M, Zlotecki RA, Gibbs CP, et al. Radiation therapy for aggressive fibromatosis: the association between local control and age. Int J Radiat Oncol Biol Phys. 2018;100(4):997–1003 Large single institution retrospective study reporting local control rates with radiotherapy and the influence of younger age.

    Article  PubMed  Google Scholar 

  19. •• Bishop AJ, Zarzour MA, Ratan R, Torres KE, Feig BW, Wang WL, et al. Long-term outcomes for patients with desmoid fibromatosis treated with radiation therapy: a 10-year update and re-evaluation of the role of radiation therapy for younger patients. Int J Radiat Oncol Biol Phys. 2019;103(5):1167–74 Large single institution retrospective study reporting the influence of younger age and tumor size on local control rates. No benefit of combine- modality treatment (with surgery) over radiotherapy alone was demonstrated.

    Article  PubMed  Google Scholar 

  20. Seidensaal K, Harrabi SB, Weykamp F, Herfarth K, Welzel T, Mechtersheimer G, et al. Radiotherapy in the treatment of aggressive fibromatosis: experience from a single institution. Radiat Oncol (London England). 2020;15(1):143.

    Article  CAS  Google Scholar 

  21. Choi SH, Yoon HI, Kim SH, Kim SK, Shin KH, Suh CO. Optimal radiotherapy strategy for primary or recurrent fibromatosis and long-term results. PLoS One. 2018;13(5):e0198134.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Couto Netto SD, Teixeira F, Menegozzo CAM, Leao-Filho HM, Albertini A, Ferreira FO, et al. Sporadic abdominal wall desmoid type fibromatosis: treatment paradigm after thirty two years. BMC Surg. 2018;18(1):37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Clark SK, Phillips RK. Desmoids in familial adenomatous polyposis. Br J Surg. 1996;83(11):1494–504.

    Article  CAS  PubMed  Google Scholar 

  24. Howard JH, Pollock RE. Intra-abdominal and abdominal wall desmoid fibromatosis. Oncol Ther. 2016;4(1):57–72.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Sturt NJ, Clark SK. Current ideas in desmoid tumours. Familial Cancer. 2006;5(3):275–85 discussion 87-8.

  26. ML DEM, Tonelli F, Quaresmini D, Lovero D, Della-Morte D, Silvestris F, et al. Desmoid tumors in familial adenomatous polyposis. Anticancer Res. 2017;37(7):3357–66.

    Article  Google Scholar 

  27. Gan M, Boothe D, Neklason DW, Samadder NJ, Frandsen J, Keener MB, et al. Outcomes and complications of radiation therapy in patients with familial adenomatous polyposis. J Gastrointest Oncol. 2017;8(4):643–9.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Nieuwenhuis MH, Mathus-Vliegen EM, Baeten CG, Nagengast FM, van der Bijl J, van Dalsen AD, et al. Evaluation of management of desmoid tumours associated with familial adenomatous polyposis in Dutch patients. Br J Cancer. 2011;104(1):37–42.

    Article  CAS  PubMed  Google Scholar 

  29. Desurmont T, Lefevre JH, Shields C, Colas C, Tiret E, Parc Y. Desmoid tumour in familial adenomatous polyposis patients: responses to treatments. Familial Cancer. 2015;14(1):31–9.

    Article  CAS  PubMed  Google Scholar 

  30. Williams PA, Bhaijee F, Rezeanu L, Hamilton RD, Vijayakumar S. Two metachronous neoplasms in the radiotherapy fields of a young man with familial adenomatous polyposis. J Investig Med High Impact Case Rep. 2013;1(2):2324709613484302.

    PubMed  PubMed Central  Google Scholar 

  31. Rosa F, Martinetti C, Piscopo F, Buccicardi D, Schettini D, Neumaier CE, et al. Multimodality imaging features of desmoid tumors: a head-to-toe spectrum. Insights Imaging. 2020;11(1):103.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Kriz J, Eich HT, Haverkamp U, Seegenschmiedt MH, Heide J, Bruns F, et al. Radiotherapy is effective for desmoid tumors (aggressive fibromatosis) - long-term results of a German multicenter study. Oncol Res Treat. 2014;37(5):255–60.

    Article  CAS  PubMed  Google Scholar 

  33. Keus RB, Nout RA, Blay JY, de Jong JM, Hennig I, Saran F, et al. Results of a phase II pilot study of moderate dose radiotherapy for inoperable desmoid-type fibromatosis--an EORTC STBSG and ROG study (EORTC 62991-22998). Ann Oncol. 2013;24(10):2672–6.

    Article  CAS  PubMed  Google Scholar 

  34. Nagata T, Demizu Y, Okumura T, Sekine S, Hashimoto N, Fuwa N, et al. Carbon ion radiotherapy for desmoid tumor of the abdominal wall: a case report. World J Surg Oncol. 2016;14(1):245.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Zreik RT, Fritchie KJ. Morphologic spectrum of desmoid-type fibromatosis. Am J Clin Pathol. 2016;145(3):332–40.

    Article  CAS  PubMed  Google Scholar 

  36. Colombo C, Bolshakov S, Hajibashi S, Lopez-Terrada L, Wang WL, Rao P, et al. ‘Difficult to diagnose’ desmoid tumours: a potential role for CTNNB1 mutational analysis. Histopathology. 2011;59(2):336–40.

    Article  PubMed  Google Scholar 

  37. Le Guellec S, Soubeyran I, Rochaix P, Filleron T, Neuville A, Hostein I, et al. CTNNB1 mutation analysis is a useful tool for the diagnosis of desmoid tumors: a study of 260 desmoid tumors and 191 potential morphologic mimics. Mod Pathol. 2012;25(12):1551–8.

    Article  PubMed  Google Scholar 

  38. Crago AM, Chmielecki J, Rosenberg M, O'Connor R, Byrne C, Wilder FG, et al. Near universal detection of alterations in CTNNB1 and Wnt pathway regulators in desmoid-type fibromatosis by whole-exome sequencing and genomic analysis. Genes Chromosom Cancer. 2015;54(10):606–15.

    Article  CAS  PubMed  Google Scholar 

  39. Penel N, Chibon F, Salas S. Adult desmoid tumors: biology, management and ongoing trials. Curr Opin Oncol. 2017;29(4):268–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Penel N, Coindre JM, Bonvalot S, Italiano A, Neuville A, Le Cesne A, et al. Management of desmoid tumours: a nationwide survey of labelled reference centre networks in France. Eur J Cancer (OxfordEngland : 1990). 2016;58:90–6.

    Article  Google Scholar 

  41. Nishida Y, Hamada S, Kawai A, Kunisada T, Ogose A, Matsumoto Y, et al. Risk factors of local recurrence after surgery in extraabdominal desmoid-type fibromatosis: a multicenter study in Japan. Cancer Sci. 2020;111(8):2935–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Lazar AJ, Tuvin D, Hajibashi S, Habeeb S, Bolshakov S, Mayordomo-Aranda E, et al. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol. 2008;173(5):1518–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Colombo C, Miceli R, Lazar AJ, Perrone F, Pollock RE, Le Cesne A, et al. CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent, multicenter validation study. Cancer. 2013;119(20):3696–702.

    Article  CAS  PubMed  Google Scholar 

  44. Dômont J, Salas S, Lacroix L, Brouste V, Saulnier P, Terrier P, et al. High frequency of beta-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management. Br J Cancer. 2010;102(6):1032–6.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Kasper B, Gruenwald V, Reichardt P, Bauer S, Hohenberger P, Haller F. Correlation of CTNNB1 mutation status with progression arrest rate in RECIST progressive desmoid-type fibromatosis treated with imatinib: translational research results from a phase 2 study of the German Interdisciplinary Sarcoma Group (GISG-01). Ann Surg Oncol. 2016;23(6):1924–7.

    Article  PubMed  Google Scholar 

  46. Walker EA, Petscavage JM, Brian PL, Logie CI, Montini KM, Murphey MD. Imaging features of superficial and deep fibromatoses in the adult population. Sarcoma. 2012;2012:215810.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Murphey MD, Ruble CM, Tyszko SM, Zbojniewicz AM, Potter BK, Miettinen M. From the archives of the AFIP: musculoskeletal fibromatoses: radiologic-pathologic correlation. Radiographics. 2009;29(7):2143–73.

    Article  PubMed  Google Scholar 

  48. Braschi-Amirfarzan M, Keraliya AR, Krajewski KM, Tirumani SH, Shinagare AB, Hornick JL, et al. Role of imaging in management of desmoid-type fibromatosis: a primer for radiologists. Radiographics : a review publication of the Radiological Society of North America. Inc. 2016;36(3):767–82.

    Google Scholar 

  49. Otero S, Moskovic EC, Strauss DC, Benson C, Miah AB, Thway K, et al. Desmoid-type fibromatosis. Clin Radiol. 2015;70(9):1038–45.

    Article  CAS  PubMed  Google Scholar 

  50. Castellazzi G, Vanel D, Le Cesne A, Le Pechoux C, Caillet H, Perona F, et al. Can the MRI signal of aggressive fibromatosis be used to predict its behavior? Eur J Radiol. 2009;69(2):222–9.

    Article  CAS  PubMed  Google Scholar 

  51. Lee JC, Thomas JM, Phillips S, Fisher C, Moskovic E. Aggressive fibromatosis: MRI features with pathologic correlation. AJR Am J Roentgenol. 2006;186(1):247–54.

    Article  PubMed  Google Scholar 

  52. Dinauer PA, Brixey CJ, Moncur JT, Fanburg-Smith JC, Murphey MD. Pathologic and MR imaging features of benign fibrous soft-tissue tumors in adults. Radiographics. 2007;27(1):173–87.

    Article  PubMed  Google Scholar 

  53. Bonvalot S, Eldweny H, Haddad V, Rimareix F, Missenard G, Oberlin O, et al. Extra-abdominal primary fibromatosis: aggressive management could be avoided in a subgroup of patients. Eur J Surg Oncol. 2008;34(4):462–8.

    Article  CAS  PubMed  Google Scholar 

  54. Ruspi L, Cananzi FCM, Sicoli F, Samà L, Renne SL, Marrari A, et al. Event-free survival in Desmoid-Type fibromatosis (DTF): A pre-post comparison of upfront surgery versus wait-and-see approach. Eur J Surg Oncol. 2020;15:S0748-7983(20):30701–0.

  55. Krieg AH, Wirth C, Lenze U, Kettelhack C, Coslovsky M, Baumhoer D, et al. Extra-abdominal desmoid tumours - further evidence for the watchful waiting policy. Swiss Med Wkly. 2019;149:w20107.

    CAS  PubMed  Google Scholar 

  56. Fiore M, Rimareix F, Mariani L, Domont J, Collini P, Le Péchoux C, et al. Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment. Ann Surg Oncol. 2009;16(9):2587–93.

    Article  PubMed  Google Scholar 

  57. Honeyman JN, Theilen TM, Knowles MA, McGlynn MM, Hameed M, Meyers P, et al. Desmoid fibromatosis in children and adolescents: a conservative approach to management. J Pediatr Surg. 2013;48(1):62–6.

    Article  PubMed  Google Scholar 

  58. The management of desmoid tumours: a joint global consensus-based guideline approach for adult and paediatric patients. Eur J Cancer (Oxford, England : 1990). 2020 Mar;127:96–107 Consensus-based guideline providing an overview of the management of desmoid tumors.

  59. Salas S, Dufresne A, Bui B, Blay JY, Terrier P, Ranchere-Vince D, et al. Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(26):3553–8.

    Article  Google Scholar 

  60. Holme H, Westbury CB, Morgenstern D, Erturan G, Tirabosco R, Pollock R, et al. An important role for initial observation in the management of paediatric desmoid fibromatosis. Clin Oncol (Royal College of Radiologists (Great Britain)). 2013;25(1):e16.

    Article  CAS  Google Scholar 

  61. Meazza C, Bisogno G, Gronchi A, Fiore M, Cecchetto G, Alaggio R, et al. Aggressive fibromatosis in children and adolescents: the Italian experience. Cancer. 2010;116(1):233–40.

    CAS  PubMed  Google Scholar 

  62. Mullen JT, Delaney TF, Kobayashi WK, Szymonifka J, Yeap BY, Chen YL, et al. Desmoid tumor: analysis of prognostic factors and outcomes in a surgical series. Ann Surg Oncol. 2012;19(13):4028–35.

    Article  PubMed  Google Scholar 

  63. Huang K, Fu H, Shi YQ, Zhou Y, Du CY. Prognostic factors for extra-abdominal and abdominal wall desmoids: a 20-year experience at a single institution. J Surg Oncol. 2009;100(7):563–9.

    Article  PubMed  Google Scholar 

  64. Nuyttens JJ, Rust PF, Thomas CR Jr, Turrisi AT 3rd. Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors: a comparative review of 22 articles. Cancer. 2000;88(7):1517–23.

    Article  CAS  PubMed  Google Scholar 

  65. Spear MA, Jennings LC, Mankin HJ, Spiro IJ, Springfield DS, Gebhardt MC, et al. Individualizing management of aggressive fibromatoses. Int J Radiat Oncol Biol Phys. 1998;40(3):637–45.

    Article  CAS  PubMed  Google Scholar 

  66. Karakousis CP, Mayordomo J, Zografos GC, Driscoll DL. Desmoid tumors of the trunk and extremity. Cancer. 1993;72(5):1637–41.

    Article  CAS  PubMed  Google Scholar 

  67. Ballo MT, Zagars GK, Pollack A, Pisters PW, Pollack RA. Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol Off J Am Soc Clin Oncol. 1999;17(1):158–67.

    Article  CAS  Google Scholar 

  68. Lev D, Kotilingam D, Wei C, Ballo MT, Zagars GK, Pisters PW, et al. Optimizing treatment of desmoid tumors. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(13):1785–91.

    Article  Google Scholar 

  69. Tsagozis P, Stevenson JD, Grimer R. Carter S. Outcome of surgery for primary and recurrent desmoid-type fibromatosis. A retrospective case series of 174 patients. Ann Med Surg (2012). 2017;17:14–9.

    Article  Google Scholar 

  70. Bataini JP, Belloir C, Mazabraud A, Pilleron JP, Cartigny A, Jaulerry C, et al. Desmoid tumors in adults: the role of radiotherapy in their management. Am J Surg. 1988;155(6):754–60.

    Article  CAS  PubMed  Google Scholar 

  71. Santti K, Beule A, Tuomikoski L, Rönty M, Jääskeläinen AS, Saarilahti K, et al. Radiotherapy in desmoid tumors: treatment response, local control, and analysis of local failures. Strahlenther Onkol. 2017;193(4):269–75.

    Article  PubMed  Google Scholar 

  72. Gluck I, Griffith KA, Biermann JS, Feng FY, Lucas DR, Ben-Josef E. Role of radiotherapy in the management of desmoid tumors. Int J Radiat Oncol Biol Phys. 2011;80(3):787–92.

    Article  PubMed  Google Scholar 

  73. Niu X, Jiang R, Hu C. Radiotherapy in the treatment of primary or recurrent unresectable desmoid tumors of the neck. Cancer Investig. 2019;37(8):387–92.

    Article  CAS  Google Scholar 

  74. Acker JC, Bossen EH, Halperin EC. The management of desmoid tumors. Int J Radiat Oncol Biol Phys. 1993;26(5):851–8.

    Article  CAS  PubMed  Google Scholar 

  75. Rüdiger HA, Ngan SY, Ng M, Powell GJ, Choong PF. Radiation therapy in the treatment of desmoid tumours reduces surgical indications. Eur J Surg Oncol. 2010;36(1):84–8.

    Article  PubMed  Google Scholar 

  76. Kiel KD, Suit HD. Radiation therapy in the treatment of aggressive fibromatoses (desmoid tumors). Cancer. 1984;54(10):2051–5.

    Article  CAS  PubMed  Google Scholar 

  77. Hong AM, Jones D, Boyle R, Stalley P. Radiation therapy as an alternative treatment for desmoid fibromatosis. Clin Oncol (Royal College of Radiologists (Great Britain)). 2018;30(9):589–92.

    Article  CAS  Google Scholar 

  78. Janssen ML, van Broekhoven DL, Cates JM, Bramer WM, Nuyttens JJ, Gronchi A, et al. Meta-analysis of the influence of surgical margin and adjuvant radiotherapy on local recurrence after resection of sporadic desmoid-type fibromatosis. Br J Surg. 2017;104(4):347–57 Meta-analysis demonstrating an association of decreased risk of recurrence with adjuvant radiotherapy.

  79. Bishop AJ, Landry JP, Roland CL, Ratan R, Feig BW, Moon BS, et al. Certain risk factors for patients with desmoid tumors warrant reconsideration of local therapy strategies. Cancer. 2020;126(14):3265–73 Large single institution retrospective study showing an increase risk of recurence for young patients, patients with extremity tumors, and patients with large tumors after local therapy with surgery, radiotherapy, or both.

  80. Merchant NB, Lewis JJ, Woodruff JM, Leung DH, Brennan MF. Extremity and trunk desmoid tumors: a multifactorial analysis of outcome. Cancer. 1999;86(10):2045–52.

    Article  CAS  PubMed  Google Scholar 

  81. Gronchi A, Casali PG, Mariani L, Lo Vullo S, Colecchia M, Lozza L, et al. Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution. J Clin Oncol Off J Am Soc Clin Oncol. 2003;21(7):1390–7.

    Article  CAS  Google Scholar 

  82. Pignatti G, Barbanti-Brodano G, Ferrari D, Gherlinzoni F, Bertoni F, Bacchini P, et al. Extraabdominal desmoid tumor. A study of 83 cases. Clin Orthop Relat Res. 2000 Jun;(375):207–13.

  83. Reitamo JJ. The desmoid tumor. IV. Choice of treatment, results, and complications. Arch Surg. 1983;118(11):1318–22.

    Article  CAS  PubMed  Google Scholar 

  84. Ballo MT, Zagars GK, Pollack A. Radiation therapy in the management of desmoid tumors. Int J Radiat Oncol Biol Phys. 1998;42(5):1007–14.

    Article  CAS  PubMed  Google Scholar 

  85. Miralbell R, Suit HD, Mankin HJ, Zuckerberg LR, Stracher MA, Rosenberg AE. Fibromatoses: from postsurgical surveillance to combined surgery and radiation therapy. Int J Radiat Oncol Biol Phys. 1990;18(3):535–40.

    Article  CAS  PubMed  Google Scholar 

  86. Peng PD, Hyder O, Mavros MN, Turley R, Groeschl R, Firoozmand A, et al. Management and recurrence patterns of desmoids tumors: a multi-institutional analysis of 211 patients. Ann Surg Oncol. 2012;19(13):4036–42.

    Article  PubMed  PubMed Central  Google Scholar 

  87. Yao X, Corbett T, Gupta AA, Kandel RA, Verma S, Werier J, et al. A systematic review of active treatment options in patients with desmoid tumours. Curr Oncol. 2014;21(4):e613–29.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Davis AM, O'Sullivan B, Turcotte R, Bell R, Catton C, Chabot P, et al. Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma. Radiother Oncol. 2005;75(1):48–53.

    Article  PubMed  Google Scholar 

  89. Daylami R, Amiri A, Goldsmith B, Troppmann C, Schneider PD, Khatri VP. Inferior vena cava leiomyosarcoma: is reconstruction necessary after resection? J Am Coll Surg. 2010;210(2):185–90.

    Article  PubMed  Google Scholar 

  90. Francis WP, Zippel D, Mack LA, DiFrancesco LM, Kurien E, Schachar NS, et al. Desmoids: a revelation in biology and treatment. Ann Surg Oncol. 2009;16(6):1650–4.

    Article  PubMed  Google Scholar 

  91. O'Dea FJ, Wunder J, Bell RS, Griffin AM, Catton C, O'Sullivan B. Preoperative radiotherapy is effective in the treatment of fibromatosis. Clin Orthop Relat Res. 2003;415:19–24.

    Article  Google Scholar 

  92. Lam AP, Gottardi CJ. β-catenin signaling: a novel mediator of fibrosis and potential therapeutic target. Curr Opin Rheumatol. 2011;23(6):562–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Roeder F, Timke C, Oertel S, Hensley FW, Bischof M, Muenter MW, et al. Intraoperative electron radiotherapy for the management of aggressive fibromatosis. Int J Radiat Oncol Biol Phys. 2010;76(4):1154–60.

    Article  PubMed  Google Scholar 

  94. Assad WA, Nori D, Hilaris BS, Shiu MH, Hajdu SI. Role of brachytherapy in the management of desmoid tumors. Int J Radiat Oncol Biol Phys. 1986;12(6):901–6.

    Article  CAS  PubMed  Google Scholar 

  95. Husain Z, Benevenia J, Uglialoro AD, Beebe KS, Patterson FR, Hameed MR, et al. An evaluation of brachytherapy and external beam radiation used with wide-margin surgical resection in the treatment of extra-abdominal desmoid tumors. Am J Orthop (Belle Mead, NJ). 2011;40(5):E78–82.

    Google Scholar 

  96. Jabbari S, Andolino D, Weinberg V, Missett BT, Law J, Wara WM, et al. Successful treatment of high risk and recurrent pediatric desmoids using radiation as a component of multimodality therapy. Int J Radiat Oncol Biol Phys. 2009;75(1):177–82.

    Article  PubMed  Google Scholar 

  97. Eaton BR, MacDonald SM, Yock TI, Tarbell NJ. Secondary malignancy risk following proton radiation therapy. Front Oncol. 2015;5:261.

    Article  PubMed  PubMed Central  Google Scholar 

  98. Xiang M, Chang DT, Pollom EL. Second cancer risk after primary cancer treatment with three-dimensional conformal, intensity-modulated, or proton beam radiation therapy. Cancer. 2020;126(15):3560–8.

    Article  PubMed  Google Scholar 

  99. Bates JE, Howell RM, Liu Q, Yasui Y, Mulrooney DA, Dhakal S, et al. Therapy-related cardiac risk in childhood cancer survivors: an analysis of the childhood cancer survivor study. J Clin Oncol Off J Am Soc Clin Oncol. 2019;37(13):1090–101.

    Article  CAS  Google Scholar 

  100. Taylor C, McGale P, Brønnum D, Correa C, Cutter D, Duane FK, et al. Cardiac structure injury after radiotherapy for breast cancer: cross-sectional study with individual patient data. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36(22):2288–96.

    Article  Google Scholar 

  101. Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368(11):987–98.

    Article  CAS  PubMed  Google Scholar 

  102. Sherman NE, Romsdahl M, Evans H, Zagars G, Oswald MJ. Desmoid tumors: a 20-year radiotherapy experience. Int J Radiat Oncol Biol Phys. 1990;19(1):37–40.

    Article  CAS  PubMed  Google Scholar 

  103. Guadagnolo BA, Zagars GK, Ballo MT. Long-term outcomes for desmoid tumors treated with radiation therapy. Int J Radiat Oncol Biol Phys. 2008;71(2):441–7.

    Article  PubMed  Google Scholar 

  104. Park HC, Pyo HR, Shin KH, Suh CO. Radiation treatment for aggressive fibromatosis: findings from observed patterns of local failure. Oncology. 2003;64(4):346–52.

    Article  PubMed  Google Scholar 

  105. Baldini EH, Wang D, Haas RL, Catton CN, Indelicato DJ, Kirsch DG, et al. Treatment guidelines for preoperative radiation therapy for retroperitoneal sarcoma: preliminary consensus of an International Expert Panel. Int J Radiat Oncol Biol Phys. 2015;92(3):602–12.

    Article  PubMed  Google Scholar 

  106. Wang D, Zhang Q, Eisenberg BL, Kane JM, Li XA, Lucas D, et al. Significant reduction of late toxicities in patients with extremity sarcoma treated with image-guided radiation therapy to a reduced target volume: results of Radiation Therapy Oncology Group RTOG-0630 Trial. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(20):2231–8.

    Article  Google Scholar 

  107. O'Sullivan B, Griffin AM, Dickie CI, Sharpe MB, Chung PW, Catton CN, et al. Phase 2 study of preoperative image-guided intensity-modulated radiation therapy to reduce wound and combined modality morbidities in lower extremity soft tissue sarcoma. Cancer. 2013;119(10):1878–84.

    Article  PubMed  Google Scholar 

  108. Haas RL, Delaney TF, O'Sullivan B, Keus RB, Le Pechoux C, Olmi P, et al. Radiotherapy for management of extremity soft tissue sarcomas: why, when, and where? Int J Radiat Oncol Biol Phys. 2012;84(3):572–80.

    Article  PubMed  Google Scholar 

  109. Ergen SA, Tiken EE, Oksuz DC, Dincbas FO, Dervisoglu S, Mandel NM, et al. The role of radiotherapy in the treatment of primary or recurrent desmoid tumors and long-term results. Balkan Med J. 2016;33(3):316–21.

    Article  PubMed  PubMed Central  Google Scholar 

  110. Rutenberg MS, Indelicato DJ, Knapik JA, Lagmay JP, Morris C, Zlotecki RA, et al. External-beam radiotherapy for pediatric and young adult desmoid tumors. Pediatr Blood Cancer. 2011;57(3):435–42.

    Article  PubMed  Google Scholar 

  111. Matsunobu T, Kunisada T, Ozaki T, Iwamoto Y, Yoshida M, Nishida Y. Definitive radiation therapy in patients with unresectable desmoid tumors: a systematic review. Jpn J Clin Oncol. 2020;50(5):568–73 Systematic review evaluating the efficacy and toxicity of definitive radiotherapy for desmoid tumors.

  112. Crago AM, Denton B, Salas S, Dufresne A, Mezhir JJ, Hameed M, et al. A prognostic nomogram for prediction of recurrence in desmoid fibromatosis. Ann Surg. 2013;258(2):347–53.

    Article  PubMed  PubMed Central  Google Scholar 

  113. Gounder MM, Mahoney MR, Van Tine BA, Ravi V, Attia S, Deshpande HA, et al. Sorafenib for advanced and refractory desmoid tumors. N Engl J Med. 2018;379(25):2417–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  114. Toulmonde M, Pulido M, Ray-Coquard I, Andre T, Isambert N, Chevreau C, et al. Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. Lancet Oncol. 2019;20(9):1263–72.

    Article  CAS  PubMed  Google Scholar 

  115. Penel N, Le Cesne A, Bui BN, Perol D, Brain EG, Ray-Coquard I, et al. Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. Ann Oncol. 2011;22(2):452–7.

    Article  CAS  PubMed  Google Scholar 

  116. van Houdt WJ, Husson O, Patel A, Jones RL, Smith MJF, Miah AB, et al. Outcome of primary desmoid tumors at all anatomic locations initially managed with active surveillance. Ann Surg Oncol. 2019;26(13):4699–706.

    Article  PubMed  Google Scholar 

  117. Orbach D, Brennan B, Bisogno G, Van Noesel M, Minard-Colin V, Daragjati J, et al. The EpSSG NRSTS 2005 treatment protocol for desmoid-type fibromatosis in children: an international prospective case series. Lancet Child Adolesc Health. 2017;1(4):284–92.

    Article  PubMed  Google Scholar 

  118. Blaauwbroek R, Groenier KH, Kamps WA, Meyboom-de Jong B, Postma A. Late effects in adult survivors of childhood cancer: the need for life-long follow-up. Ann Oncol. 2007;18(11):1898–902.

    Article  CAS  PubMed  Google Scholar 

  119. Luo J, Jin K, Qian S, Ma X, Pan Z, Yao W, et al. Single institution experience of split course radiotherapy in patients with desmoid tumors. Onco Targets Ther. 2019;12:1741–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  120. Schmitt G, Mills EE, Levin V, Smit BJ, Boecker H, Pape H. Radiotherapy of aggressive fibromatosis. Eur J Cancer (Oxford England : 1990). 1992;28A(4-5):832–5.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, University of Florida College of Medicine, 2015 North Jefferson Street, Jacksonville, FL, 32206, USA

    Wen Shen Looi MBBS, FRCR, Daniel J. Indelicato MD & Michael S. Rutenberg MD, PhD

Authors
  1. Wen Shen Looi MBBS, FRCR
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel J. Indelicato MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael S. Rutenberg MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel J. Indelicato MD.

Ethics declarations

Conflict of Interest

Wen Shen Looi declares that he has no conflict of interest.

Daniel J. Indelicato declares that he has no conflict of interest.

Michael S. Rutenberg declares that he has no conflict of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Sarcoma

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Looi, W.S., Indelicato, D.J. & Rutenberg, M.S. The Role of Radiation Therapy for Symptomatic Desmoid Tumors. Curr. Treat. Options in Oncol. 22, 34 (2021). https://doi.org/10.1007/s11864-021-00831-6

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11864-021-00831-6

Keywords

Search

Navigation